Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple myeloma and patients with bone metastases fro...
Main Authors: | Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-04-01
|
Series: | Journal of Bone Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137422000069 |
Similar Items
-
A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
by: Yanhua Ding, et al.
Published: (2023-10-01) -
A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva<sup>®</sup>) Related Osteonecrosis of the Jaw: A Retrospective Study
by: Zineb Assili, et al.
Published: (2021-05-01) -
Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico
by: Fernando Carlos-Rivera, et al.
Published: (2022-04-01) -
Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years
by: Chi Zhang, et al.
Published: (2018-11-01) -
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
by: Prasad Apsangikar, et al.
Published: (2022-04-01)